Literature DB >> 7061686

Evidence for dopaminergic control of circadian variations in thyrotropin secretion.

J R Sowers, R A Catania, J M Hershman.   

Abstract

This study examines the influence of dopamine of recumbent circadian secretory patterns of plasma TSH. Seven euthyroid men were studied during a control (no medication) and a bromocriptine period (2.5 mg bromocriptine three times a day for 5 days). In the control period, a clear daily pattern in plasma TSH was evidenced, with highest levels occurring during the late evening presleep period and the fist few hours after the onset of nocturnal sleep. During the control period, recumbent 24-h plasma TSH was linearly correlated (gamma = 0.41; P less than 0.05) with clock time. Bromocriptine lowered the mean 24-h TSH from a control level of 2.1 +/- 0.2 to 1.1 microunits/ml. Further, bromocriptine eliminated the early nocturnal TSH surge and the correlation of plasma TSH with clock time. Thus, circadian variations in plasma TSH levels may be modulated, in part, by a dopaminergic mechanism. However, we cannot rule out a direct effect of bromocriptine on the anterior pituitary resulting in decreased late evening rises in plasma TSH.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061686     DOI: 10.1210/jcem-54-4-673

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Multifactorial control of the 24-hour secretory profiles of pituitary hormones.

Authors:  E Van Cauter; S Refetoff
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

2.  Pulsatile secretion of thyrotropin in children.

Authors:  S Loche; V Cherubini; E Bartolotta; A Lampis; D Carta; P Tomasi; C Pintor
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

3.  Recovery of serum TSH and thyroid hormones after 3'isopropyl-3,5-diiodo-L-thyronine (DIIP) treatment: absence of inhibiting effect of bromocriptine on TSH secretion and evidence for autoregulation of serum T3 levels.

Authors:  N A Salomon-Montavon; A G Burger
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

4.  TRH: pathophysiologic and clinical implications.

Authors:  C R Pickardt; P C Scriba
Journal:  Acta Neurochir (Wien)       Date:  1985       Impact factor: 2.216

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.